21 hrs ago
AstraZeneca PLC Closes in on Site for New $500 Million Home in Cambridge
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just south of the English city the most likely site, property industry sources said.
Sun May 19, 2013
U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying
Insiders may sell shares for any number of reasons, but conventional wisdom is that insiders really only buy shares of a company for one reason -- they believe the stock price will move higher and they want to profit from it.
AstraZeneca Given "Neutral" Rating at JP Morgan Cazenove
's stock had its "neutral" rating reaffirmed by JP Morgan Cazenove in a research note issued on Monday, ARN reports.
AstraZeneca Stock Rating Reaffirmed by Panmure Gordon
's stock had its "hold" rating reiterated by equities research analysts at Panmure Gordon in a research note issued to investors on Monday, AnalystRatingsNetwork.com reports.
Thu May 16, 2013
AstraZeneca PLC, Cubist Pharmaceuticals, Inc., Astellas Pharma Inc....
AstraZeneca PLC , Cubist Pharmaceuticals, Inc. , Astellas Pharma Inc. Said to Make Bids for Optimer Pharmaceuticals, Inc.
Tue May 14, 2013
AstraZeneca plc (AZN): How Does It Stack Up?
Dividend income accounts for around two-thirds of total returns, the actual rate of return taking into account both capital and income appreciation.
Mon May 13, 2013
Assessing Your Asthma is Key to Taking Control
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year.
Sun May 12, 2013
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
This article is the second in a three part series about Array BioPharma Inc. , a biopharmaceutical company that is developing small molecule drug candidates for the treatment of cancers and other diseases.
AstraZeneca Rating Reiterated by JP Morgan Cazenove
's stock had its "neutral" rating reiterated by equities research analysts at JP Morgan Cazenove in a research note issued to investors on Tuesday, AnalystRatingsNetwork.com reports.
Fri May 10, 2013
AstraZeneca Receives "Hold" Rating from Deutsche Bank
Shares of AstraZeneca traded down 0.08% during mid-day trading on Wednesday, hitting $51.54. AstraZeneca has a 52 week low of $39.72 and a 52 week high of $52.27. The stock's 50-day moving average is currently $50.92. The company has a market cap of $64.425 billion and a P/E ratio of 11.41. Other equities research analysts have also recently issued ... (more)
Wed May 08, 2013
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
On May 8, 2013, Pozen reported financial results for the first quarter 2013. Pozen reported revenues in the quarter of $1.415 million, driven entirely by royalties on $19.7 million in worldwide sales of Vimovo at AstraZeneca .
A twist in Pozen's 'nightmare' partnership
Pozen's "nightmare" partnership is changing its terms, but what that might mean for the Chapel Hill company remains unclear.
AstraZeneca Receives "Equal Weight" Rating from Morgan Stanley
's stock had its "equal weight" rating restated by equities researchers at Morgan Stanley in a report issued on Wednesday, Analyst Ratings Network reports.
Tue May 07, 2013
VIVUS, Inc. Announces Former President U.S. and CEO North America,...
VIVUS, Inc. Announces Richard Fante , Former President U.S. and CEO North America, AstraZeneca PLC , to Serve as Senior Advisor Staying up-to-date has never been simpler.
The Boulder County Business Report
Array reports decline in revenue, income
Cancer drug research company Array BioPharma Inc. reported lower revenue and higher losses for the most recent quarter compared with the same period a year ago.
The Japan Times
Lessons from the Iressa case
The Supreme Court on April 12 upheld two high court rulings that said the state and the Japanese unit of British drug maker AstraZeneca PLC bore no liability for fatal side effects caused by the lung cancer drug Iressa.
Mon May 06, 2013
Bristol-Myers Squibb Company, AstraZeneca PLC Release: Sub-Group...
Bristol-Myers Squibb Company , AstraZeneca PLC Release: Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients With Lipodystrophy During a 12-Month Period Staying up-to-date has never been simpler.
Sun May 05, 2013
AstraZeneca Receives "Hold" Rating from Jefferies Group
's stock had its "hold" rating reaffirmed by research analysts at Jefferies Group in a report released on Thursday, StockRatingsNetwork reports.
AstraZeneca Given Neutral Rating at JP Morgan Cazenove
's stock had its "neutral" rating reiterated by equities research analysts at JP Morgan Cazenove in a research note issued to investors on Thursday, ARN reports.
Sat May 04, 2013
Pharma. & Medical Packaging News
A.P. Pharma Appoints New Management Team
A.P. Pharma, Inc. , a specialty pharmaceutical company, today announced that its Board of Directors has appointed a new management team to lead the Company.